Publications

Detailed Information

Anti-neuroinflammatory Activity of Nobiletin on Suppression of Microglial Activation

DC Field Value Language
dc.contributor.authorCui, Yanji-
dc.contributor.authorWu, Jinji-
dc.contributor.authorPark, Deok-Bae-
dc.contributor.authorJung, Sung-Cherl-
dc.contributor.authorHong, Jeong Yun-
dc.contributor.authorLee, Sun-Ryung-
dc.contributor.authorKim, Sang Jeong-
dc.contributor.authorEun, Su-Yong-
dc.contributor.authorKim, Soon-Jong-
dc.contributor.authorKim, Se-Jae-
dc.contributor.authorMaeng, Young-Hee-
dc.date.accessioned2012-05-22T02:40:53Z-
dc.date.available2012-05-22T02:40:53Z-
dc.date.issued2010-11-
dc.identifier.citationBIOLOGICAL & PHARMACEUTICAL BULLETIN; Vol.33 11; 1814-1821ko_KR
dc.identifier.issn0918-6158-
dc.identifier.urihttps://hdl.handle.net/10371/76211-
dc.description.abstractA growing body of evidence suggests that nobiletin (5,6,7,8,3`,4`-hexamethoxy flavone) from the peel of citrus fruits, enhances the damaged cognitive function in disease animal models. However, the neuroprotective mechanism has not been clearly elucidated. Since nobiletin has shown anti-inflammatory effects in several tissues, we investigated whether nobiletin suppresses excessive microglial activation implicated in neurotoxicity in lipopolysaccharide (LPS)-stimulated BV-2 microglia cell culture models. Release of nitric oxide (NO), the major inflammatory mediator in microglia, was markedly suppressed in a dose-dependent manner following nobiletin treatment (1-50 mu M) in LPS-stimulated BV-2 microglia cells. The inhibitory effect of nobiletin was similar to that of minocycline, a well-known microglial inactivator. Nobiletin significantly inhibited the release of the pro-inflammatory cytokine tumor necrosis factor (TNF-alpha) and interleukin-1 beta (IL-1 beta). LPS-induced phosphorylations of extracellular signal-regulated kinase (ERK), c-Jun NH(2)-terminal kinase (JNK), and p38 mitogen-activated protein kinases (MAPKs) were also significantly inhibited by nobiletin treatment. In addition, nobiletin markedly inhibited the LPS-induced pro-inflammatory transcription factor nuclear factor kappa B (NF-kappa B) signaling pathway by suppressing nuclear NF-kappa B translocation from the cytoplasm and subsequent expression of NF-kappa B in the nucleus. Taken together, these results may contribute to further exploration of the therapeutic potential and molecular mechanism of nobiletin in relation to neuroinflammation and neurodegenerative diseases.ko_KR
dc.language.isoenko_KR
dc.publisherPHARMACEUTICAL SOC JAPANko_KR
dc.subjectnobiletinko_KR
dc.subjectneuroinflammationko_KR
dc.subjectneurodegenerationko_KR
dc.subjectcitrusko_KR
dc.subjectnuclear factor kappa Bko_KR
dc.subjectmicrogliako_KR
dc.titleAnti-neuroinflammatory Activity of Nobiletin on Suppression of Microglial Activationko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor우진지-
dc.contributor.AlternativeAuthor정성철-
dc.contributor.AlternativeAuthor맹양희-
dc.contributor.AlternativeAuthor이선령-
dc.contributor.AlternativeAuthor김세재-
dc.contributor.AlternativeAuthor홍정윤-
dc.contributor.AlternativeAuthor박덕배-
dc.contributor.AlternativeAuthor김순종-
dc.contributor.AlternativeAuthor은수용-
dc.contributor.AlternativeAuthor김상정-
dc.citation.journaltitleBIOLOGICAL & PHARMACEUTICAL BULLETIN-
dc.description.citedreferenceYrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496-
dc.description.citedreferenceRupalla K, 1998, ACTA NEUROPATHOL, V96, P172-
dc.description.citedreferenceZhang ZG, 1997, BRAIN RES, V744, P189-
dc.description.citedreferenceBREITNER JCS, 1994, NEUROLOGY, V44, P227-
dc.description.citedreferenceCaudle WM, 2009, EXP NEUROL, V220, P230, DOI 10.1016/j.expneurol.2009.09.027-
dc.description.citedreferenceVan Damme P, 2009, CURR OPIN NEUROL, V22, P486, DOI 10.1097/WCO.0b013e32832ffbe3-
dc.description.citedreferenceBreitner JCS, 2009, NEUROLOGY, V72, P1899, DOI 10.1212/WNL.0b013e3181a18691-
dc.description.citedreferenceMin SS, 2009, NEUROSCI LETT, V456, P20, DOI 10.1016/j.neulet.2009.03.079-
dc.description.citedreferenceMatsuzaki K, 2008, EUR J PHARMACOL, V578, P194, DOI 10.1016/j.ejphar.2007.09.028-
dc.description.citedreferenceKaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008-
dc.description.citedreferenceParameshwaran K, 2008, EXP NEUROL, V210, P7, DOI 10.1016/j.expneurol.2007.10.008-
dc.description.citedreferenceOnozuka H, 2008, J PHARMACOL EXP THER, V326, P739, DOI 10.1124/jpet.108.140293-
dc.description.citedreferenceCho IH, 2008, BRAIN, V131, P3019, DOI 10.1093/brain/awn230-
dc.description.citedreferenceLU L, 2009, CNS NEUROL DISORD-DR, V9, P232-
dc.description.citedreferenceWang LQ, 2009, TRIBOL T, V52, P59, DOI 10.1109/CCCM.2009.5267991-
dc.description.citedreferenceKim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040-
dc.description.citedreferenceMin SS, 2009, BIOCHEM BIOPH RES CO, V383, P93, DOI 10.1016/j.bbrc.2009.03.133-
dc.description.citedreferenceRyu J, 2000, J BIOL CHEM, V275, P29955-
dc.description.citedreferenceCombs CK, 2001, J NEUROSCI, V21, P1179-
dc.description.citedreferenceTikka T, 2001, J NEUROSCI, V21, P2580-
dc.description.citedreferencein `t Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178-
dc.description.citedreferenceChoi SH, 2003, J NEUROSCI, V23, P5877-
dc.description.citedreferenceSzekely CA, 2004, NEUROEPIDEMIOLOGY, V23, P159, DOI 10.1159/000078501-
dc.description.citedreferenceROSI S, 2004, J NEUROINFLAMM, V1, P12-
dc.description.citedreferenceMin KJ, 2004, GLIA, V48, P197, DOI 10.1002/glia.20069-
dc.description.citedreferenceEun SY, 2004, BIOCHEM BIOPH RES CO, V325, P320, DOI 10.1016/j.bbrc.2004.10.035-
dc.description.citedreferenceOchfeld E, 2010, STROKE, V41, P325, DOI 10.1161/STROKEAHA.109.570374-
dc.description.citedreferenceOck J, 2010, BIOCHEM PHARMACOL, V79, P596, DOI 10.1016/j.bcp.2009.09.026-
dc.description.citedreferencePyo H, 1999, J BIOL CHEM, V274, P34584-
dc.description.citedreferenceCombs CK, 2000, J NEUROSCI, V20, P558-
dc.description.citedreferenceWu CK, 2005, EXP NEUROL, V195, P484, DOI 10.1016/j.expneurol.2005.06.020-
dc.description.citedreferenceNagase H, 2005, BIOCHEM BIOPH RES CO, V337, P1330, DOI 10.1016/j.bbrc.2005.10.001-
dc.description.citedreferenceEun SY, 2006, EXP MOL MED, V38, P310-
dc.description.citedreferenceChoi SY, 2007, BIOL PHARM BULL, V30, P772-
dc.description.citedreferenceNakajima A, 2007, J PHARMACOL EXP THER, V321, P784, DOI 10.1124/jpet.106.117010-
dc.description.citedreferenceChoi SY, 2007, J ETHNOPHARMACOL, V113, P149, DOI 10.1016/j.jep.2007.05.021-
dc.description.citedreferenceNakajima A, 2007, J PHARMACOL SCI, V105, P122, DOI 10.1254/jphs.SC0070155-
dc.description.citedreferenceCHRISTENSEN DZ, 2008, NEUROBIOL AGING, V31, P1153-
dc.description.citedreferenceOck J, 2009, PHARMACOL RES, V59, P414, DOI 10.1016/j.phrs.2009.02.008-
dc.description.citedreferenceLees AJ, 2009, LANCET, V373, P2055-
dc.description.citedreferenceYamamoto Y, 2009, BRAIN RES, V1295, P218, DOI 10.1016/j.brainres.2009.07.081-
dc.description.citedreferencePark GH, 2010, NITRIC OXIDE-BIOL CH, V22, P18, DOI 10.1016/j.niox.2009.10.008-
dc.description.citedreferenceBOCCHINI V, 1992, J NEUROSCI RES, V31, P616-
dc.description.citedreferenceBLASI E, 1990, J NEUROIMMUNOL, V27, P229-
dc.description.tc2-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share